Cytokinetics (CYTK) Competitors $48.87 +2.13 (+4.56%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CYTK vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte Cytokinetics (NASDAQ:CYTK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Which has stronger valuation and earnings, CYTK or TEVA? Cytokinetics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$3.22M1,791.66-$526.24M-$5.38-9.08Teva Pharmaceutical Industries$16.77B1.49-$559M-$0.85-25.99 Is CYTK or TEVA more profitable? Teva Pharmaceutical Industries has a net margin of -5.73% compared to Cytokinetics' net margin of -17,906.25%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Teva Pharmaceutical Industries -5.73%42.92%7.25% Does the MarketBeat Community believe in CYTK or TEVA? Teva Pharmaceutical Industries received 520 more outperform votes than Cytokinetics when rated by MarketBeat users. However, 79.74% of users gave Cytokinetics an outperform vote while only 67.81% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes80779.74% Underperform Votes20520.26% Teva Pharmaceutical IndustriesOutperform Votes132767.81% Underperform Votes63032.19% Which has more risk and volatility, CYTK or TEVA? Cytokinetics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Does the media prefer CYTK or TEVA? In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Cytokinetics. MarketBeat recorded 27 mentions for Teva Pharmaceutical Industries and 13 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.85 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 12 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in CYTK or TEVA? 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 3.4% of Cytokinetics shares are held by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend CYTK or TEVA? Cytokinetics currently has a consensus price target of $84.07, indicating a potential upside of 72.02%. Teva Pharmaceutical Industries has a consensus price target of $20.88, indicating a potential downside of 5.50%. Given Cytokinetics' higher probable upside, research analysts plainly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.75Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCytokinetics beats Teva Pharmaceutical Industries on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.77B$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-9.0810.55135.2017.16Price / Sales1,791.66194.011,120.31115.67Price / CashN/A57.1640.5837.88Price / Book-12.405.104.754.78Net Income-$526.24M$151.51M$118.50M$225.60M7 Day Performance0.45%-2.13%-1.85%-1.21%1 Month Performance2.52%-3.14%11.27%3.09%1 Year Performance9.04%11.54%29.92%16.48% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.1299 of 5 stars$48.87+4.6%$84.07+72.0%+36.8%$5.77B$3.22M-9.08250Analyst ForecastTEVATeva Pharmaceutical Industries1.8805 of 5 stars$16.67+1.0%$19.67+18.0%+112.2%$18.89B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6115 of 5 stars$176.80-1.4%$253.69+43.5%+0.7%$17.23B$2.46B-21.7710,600MRNAModerna4.2664 of 5 stars$41.75-0.2%$79.50+90.4%-54.3%$16.07B$5.06B-7.195,600Analyst DowngradeVTRSViatris2.0581 of 5 stars$12.64+0.1%$13.67+8.1%+19.8%$15.09B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2652 of 5 stars$18.87+5.8%$33.33+76.6%+636.9%$13.92B$700,000.00-63.68105News CoverageGMABGenmab A/S4.2355 of 5 stars$20.08-0.4%$45.20+125.1%-33.5%$13.29B$19.84B19.582,204Positive NewsHigh Trading VolumeRDYDr. Reddy's Laboratories1.8457 of 5 stars$14.74+1.9%$17.00+15.3%+15.8%$12.30B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8116 of 5 stars$126.00+1.9%$178.71+41.8%+31.8%$12.04B$1.64B98.971,314Analyst ForecastCTLTCatalent2.7788 of 5 stars$63.48+0.7%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.6049 of 5 stars$90.51+3.2%$147.50+63.0%+45.4%$11.28BN/A-19.07160Analyst ForecastInsider Trade Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Moderna Alternatives Viatris Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Catalent Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts